公开(公告)号：US06486305B1

公开(公告)日：2002-11-26

申请号：US09639987

申请日：2000-08-16

申请人： Stuart Peltz ,  Kevin Czaplinski ,  Youmin Weng

发明人： Stuart Peltz ,  Kevin Czaplinski ,  Youmin Weng

IPC分类号： A23J100

CPC分类号： C07K14/4703

摘要： This invention provides a method of modulating translation termination efficiency of mRNA and/or promoting degradation of abberant transcripts. Also, this invention provides a method of screening for a drug active involved in enhancing translation termination and a method for identifying a disease state involving defective the protein complex. This invention provides a purified complex comprising an amount of a human Upf1p protein, a peptidyl eucaryotic release factor 1 (eRF1) and a peptidyl eucaryotic release factor 3 (eRF3) effective to modulate translation termination. Further, this invention provides an expression vector which comprises a nucleic acid encoding a human Upf1p protein, a peptidyl eucaryotic release factor 1 (eRF1) and a peptidyl eucaryotic release factor 3 (eRF3) operably linked to a regulatory element. This invention provides an antibody which binds to the complex comprising an amount of a human Upf1p protein, a peptidyl eucaryotic release factor 1 (eRF1) and a peptidyl eucaryotic release factor 3 (eRF3) effective to modulate translation termination. This invention provides an agent which inhibits or modulates the binding of human Upf1p to eRF1 or eRF3 The agent may inhibit or facilitate the binding of human Upf1p to eRF1 or eRF3.

摘要翻译： 本发明提供了调节mRNA的翻译终止效率和/或促进不良转录物降解的方法。 此外，本发明提供了筛选涉及增强翻译终止的药物活性的方法以及鉴定涉及蛋白质复合物缺陷的疾病状态的方法。本发明提供了一种纯化的复合物，其包含一定量的人Upf1p蛋白，一种肽基真核 释放因子1（eRF1）和有效调节翻译终止的肽基真核生物释放因子3（eRF3）。 此外，本发明提供了一种表达载体，其包含编码人Upf1p蛋白的核酸，与调控元件可操作地连接的肽基真核生物释放因子1（eRF1）和肽基真核生物释放因子3（eRF3）。本发明提供抗体 其结合复合物，其包含一定量的人Upf1p蛋白，肽基真核生物释放因子1（eRF1）和有效调节翻译终止的肽基真核生物释放因子3（eRF3）。 本发明提供抑制或调节人Upf1p与eRF1或eRF3的结合的试剂。该试剂可抑制或促进人Upf1p与eRF1或eRF3的结合。